Yidu Tech, Inc. (2158) AI Stock Analysis

• Market Cap: HK$4.50B
• Dividend Yield: N/A
• Average Volume (3M): 7.77M
• Price to Earnings (P/E): ―
• Beta (1Y): 1.70
• Revenue Growth: -12.31%
• EPS Growth: 41.72%
• Country: HK
• Employees: 866
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Healthcare Information Services
• EPS (TTM): -0.08
• Shares Outstanding: 1,070,634,900
• 10 Day Avg. Volume: 5,926,266
• 30 Day Avg. Volume: 7,773,888
• PEG Ratio: 1.23
• Price to Book (P/B): 1.55
• Price to Sales (P/S): 8.53
• P/FCF Ratio: -17.38
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 39 Underperform
• Price Target: HK$4.50 ▼(-19.35% Downside)

Yidu Tech, Inc. faces significant financial and technical challenges. The most impactful factors are the company's negative profitability and bearish technical indicators. The valuation is also concerning with a negative P/E ratio. These factors collectively result in a low overall stock score.

Yidu Tech, Inc. Business Overview & Revenue Model

Company Description

Yidu Tech, Inc. (2158) is a leading healthcare technology company based in China, specializing in data-driven healthcare solutions. The company operates primarily in the healthcare information technology sector, providing innovative platforms and services that enhance healthcare delivery through data analytics, artificial intelligence, and cloud computing. Yidu Tech focuses on enabling healthcare providers, pharmaceutical companies, and public health organizations to optimize their operations and improve patient outcomes through its advanced software products and analytics services.

How the Company Makes Money

Yidu Tech generates revenue through multiple key streams, primarily by offering subscription-based software services and analytics solutions to healthcare institutions and organizations. The company charges clients for access to its data platforms and analytics tools, which are critical for improving operational efficiency and patient care. Additionally, Yidu Tech engages in partnerships with healthcare providers and pharmaceutical companies to develop tailored solutions, which can also provide lucrative revenue opportunities. The company may also benefit from government contracts and initiatives aimed at enhancing healthcare infrastructure, contributing significantly to its earnings.

Yidu Tech, Inc. Financial Statement Overview

Summary

Yidu Tech, Inc. faces challenges in revenue growth and profitability, as reflected in its income statement. The balance sheet is stable with low leverage, but profitability needs improvement to enhance returns. Cash flow management is crucial, with a need to turn negative operating cash flows into positive territory.

Income Statement

Yidu Tech, Inc. has experienced declining revenue growth, with a negative growth rate of -8.34% in the most recent year. The company also faces challenges in profitability, as evidenced by negative net profit and EBIT margins. The gross profit margin has decreased from the previous year, indicating pressure on cost management. Overall, the income statement reflects a need for improvement in revenue generation and cost control.

Balance Sheet

The balance sheet shows a low debt-to-equity ratio of 0.03, indicating conservative leverage. However, the return on equity is negative, reflecting ongoing losses. The equity ratio remains strong at approximately 83.6%, suggesting a solid equity base relative to total assets. Despite the low leverage, the company needs to improve profitability to enhance shareholder returns.

Cash Flow

Yidu Tech, Inc. has shown a significant increase in free cash flow growth, but the operating cash flow remains negative, indicating operational challenges. The free cash flow to net income ratio is positive, suggesting that the company is generating cash relative to its net losses. However, the negative operating cash flow to net income ratio highlights the need for better cash flow management.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	780.04M	714.98M	807.08M	804.70M	1.24B	867.04M
Gross Profit	319.82M	239.18M	339.44M	274.50M	396.89M	327.34M
EBITDA	-314.96M	-89.62M	-170.77M	-579.98M	-715.70M	-3.65B
Net Income	-162.62M	-117.79M	-194.94M	-627.97M	-762.32M	-3.70B
Balance Sheet
Total Assets	4.67B	4.69B	4.82B	4.91B	4.72B	5.25B
Cash, Cash Equivalents and Short-Term Investments	3.39B	3.30B	3.70B	3.75B	3.77B	4.63B
Total Debt	55.91M	129.54M	95.20M	14.13M	52.16M	26.43M
Total Liabilities	680.97M	711.37M	732.21M	755.36M	715.34M	497.71M
Stockholders Equity	3.93B	3.92B	4.02B	4.08B	3.99B	4.73B
Cash Flow
Free Cash Flow	-154.49M	-350.78M	-367.20M	-374.60M	-672.14M	-350.73M
Operating Cash Flow	-152.54M	-248.81M	-326.38M	-357.01M	-614.68M	-331.68M
Investing Cash Flow	-213.97M	116.71M	466.90M	-2.34B	3.39B	-3.87B
Financing Cash Flow	35.33M	20.04M	82.21M	361.45M	-35.23M	4.26B

Yidu Tech, Inc. Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 5.58
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:2158, the sentiment is Negative. The current price of 5.58 is above the 20-day moving average (MA) of 5.45, below the 50-day MA of 5.81, and below the 200-day MA of 6.15, indicating a bearish trend. The MACD of -0.24 indicates Positive momentum. The RSI at 35.11 is Neutral, neither overbought nor oversold. The STOCH value of 14.42 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for HK:2158.

Yidu Tech, Inc. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
1763	79 Outperform	HK$6.77B	14.77	8.59%	2.67%	13.59%	6.31%
2877	73 Outperform	HK$6.66B	7.47	10.85%	5.91%	-20.64%	-25.39%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
2159	46 Neutral	HK$333.20M	―	-35.99%	―	-5.38%	63.93%
2616	42 Neutral	HK$8.81B	-19.44	-95.84%	―	-55.64%	-158.67%
2251	40 Neutral	HK$1.14B	-6.19	-12.97%	―	-32.17%	-1.20%
2158	39 Underperform	HK$4.50B	―	-2.97%	―	-12.31%	41.72%

Yidu Tech, Inc. Corporate Events

Yidu Tech Inc. Engages in Total Return Swap to Hedge Share Price Exposure

Yidu Tech Inc. has announced that a subsidiary has entered into a Total Return Swap (TRS) transaction with a counterparty, with a maximum equity notional amount of approximately HK$54,404,700. The TRS transaction, which is set for a term of approximately three years, is designed to hedge the company’s exposure to future share price appreciation, particularly in relation to its Post-IPO Share Award Scheme. The board believes the transaction terms are fair and reasonable, serving the interests of the company and its shareholders. The transaction is not subject to reporting or approval requirements under the Listing Rules, as it does not meet the applicable percentage ratios.

The most recent analyst rating on (HK:2158) stock is a Hold with a HK$6.00 price target. To see the full list of analyst forecasts on Yidu Tech, Inc. stock, see the HK:2158 Stock Forecast page.

Yidu Tech Secures Phase III Clinical Study Project for AI-Driven Eye Drop

Yidu Tech Inc. announced that its associate, Tianjin Happy Life Technology Co., Ltd., has successfully secured a bid for a Phase III Clinical Study Project of Recombinant Human Neurogenesis Factor (SMR001) Eye Drop from Shandong Yandu Biotechnology Co., Ltd., valued at approximately RMB55.8 million. This development underscores Yidu Tech’s commitment to improving healthcare service efficiency and accessibility through AI-driven solutions, reinforcing its position in the healthcare industry by enabling precise decision-making and accelerating pharmaceutical development.

The most recent analyst rating on (HK:2158) stock is a Hold with a HK$6.00 price target. To see the full list of analyst forecasts on Yidu Tech, Inc. stock, see the HK:2158 Stock Forecast page.

Yidu Tech Inc. Successfully Passes All Resolutions at AGM

Yidu Tech Inc. announced that all proposed resolutions were passed at its Annual General Meeting held on August 29, 2025. The resolutions included the adoption of financial statements, re-election of directors, and re-appointment of auditors. The approval of these resolutions reflects shareholder support for the company’s current management and strategic direction.

The most recent analyst rating on (HK:2158) stock is a Hold with a HK$6.50 price target. To see the full list of analyst forecasts on Yidu Tech, Inc. stock, see the HK:2158 Stock Forecast page.